6-1-1-5　ⓔ文献

  1. Masuho Y, Tomibe K, et al: Development of an intravenous gamma–globulin with Fc activities. I. Preparation and characterization of S–sulfonated human gamma–globulin. Vox Sang, 1977; 32: 175–181.

  2. Radosevich M, Burnouf T: Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang, 2010; 98: 12–28.

  3. Ballow M: Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol, 2014; 14: 509–515.

  4. Nagelkerke SQ, Kuijpers TW: Immunomodulation by IVIG and the Role of Fc–Gamma Receptors: Classic Mechanisms of Action after all? Front Immunol, 2015; 5: 674.

  5. Schwab I, Nimmerjahn F: Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol, 2013; 13: 176–189.

  6. Yu Z1, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody–mediated autoimmune diseases. N Engl J Med, 1999; 340: 227–228.

  7. Othy S, Hegde P, et al: Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine–1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol, 2013; 190: 4535–4541.

  8. De Groot AS, Moise L, et al: Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood, 2008; 112: 3303–3311.

  9. Wiedeman AE, Santer DM, et al: Contrasting mechanisms of interferon–α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll–like receptor agonists. Arthritis Rheum, 2013; 65: 2713–2723.

  10. Nobile–Orazio E, Cocito D, et al: Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol, 2012; 11: 493–502.

  11. Mulhearn B, Bruce IN: Indications for IVIG in rheumatic diseases. Rheumatology (Oxford), 2015; 54: 383–391.

  12. Lünemann JD, Nimmerjahn F, et al: Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol, 2015; 11: 80–89.

  13. Cruz DN, Antonelli M, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA, 2009; 301: 2445–2452.

  14. Ueki Y, Sagawa A, et al: A multicenter study of leukocytapheresis in rheumatoid arthritis. Clin Exp Rheumatol, 2007; 25: 810–816.

  15. Mitsuyama K, Yamasaki H, et al: Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease. Curr Pharm Des, 2009; 15: 2110–2119.

  16. Hanai H, Takeda Y, et al: The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol, 2011; 163: 50–58.